DOACs versus VKAs to prevent repeat clots in low‑risk antiphospholipid syndrome
Official title: Real-world Observational Study to Evaluate the Effectiveness and Safety of Direct Oral Anticoagulants Compared With Vitamin K Antagonists for Secondary Thrombosis Prevention in Low-risk Thrombotic Antiphospholipid Syndrome Patients
Run by Infanta Leonor University Hospital · NCT07372170 · Data updated 2026-11-12
This project will see if direct oral anticoagulants (DOACs) work as well and are as safe as vitamin K antagonists (VKAs) to prevent repeat venous clots in adults with low‑risk thrombotic antiphospholipid syndrome.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 600 (estimated) |
| Sponsor | Infanta Leonor University Hospital Academic / other |
| Locations | 2 sites (Madrid, Madrid and 1 other locations) |
| Status | Recruiting |
| Started | December 1, 2025 |
| Main results expected | December 31, 2028 |
| Study ends | December 31, 2028 |
| Registry record updated | January 30, 2026 |
| Trial ID | NCT07372170 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults with thrombotic APS whose prior event was venous thrombosis and who have single or double antiphospholipid antibody positivity and are on long‑term DOAC or VKA therapy are the ideal candidates.
✕Probably not a fit
Patients with triple antiphospholipid antibody positivity, prior arterial thrombosis, anticoagulation for other indications, or those under 18 are unlikely to benefit from conclusions aimed at this low‑risk adult group.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This ambispective observational study compares outcomes in adults with prior venous thrombosis and a low‑risk antiphospholipid antibody profile who are treated with either DOACs or VKAs in routine clinical practice. Investigators will collect retrospective and prospective clinical data to compare thrombotic recurrence and bleeding events between the two anticoagulant strategies. Eligible patients must have at least two weeks of continuous anticoagulation and are excluded if they have triple antibody positivity or a history of arterial thrombosis. The study is being conducted at two university hospitals in Madrid and reflects real‑world prescribing and monitoring.
Why it matters
Potential benefit: If results show comparable protection and safety, clinicians could have stronger evidence to offer DOACs as a simpler alternative to VKAs for selected low‑risk APS patients.
How similar studies have gone: Randomized trials raised safety concerns about DOACs in high‑risk APS, while smaller observational series suggest DOACs may be acceptable in carefully selected low‑risk venous APS patients, but overall evidence remains limited.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Adults (≥18 years) with a diagnosis of thrombotic antiphospholipid syndrome. * Low-risk antiphospholipid syndrome defined by previous venous thrombosis and a single or double positive antiphospholipid antibody profile (lupus anticoagulant, anticardiolipin antibodies, and/or anti-beta-2-glycoprotein I antibodies). * Patients receiving long-term anticoagulant treatment with direct oral anticoagulants or vitamin K antagonists according to routine clinical practice. * At least 2 weeks of continuous anticoagulant treatment before study inclusion. Exclusion Criteria: * Age \<18 years. * Triple antiphospholipid antibody positivity. * History of arterial thrombosis. * Anticoagulation for indications other than secondary prevention of venous thrombosis related to antiphospholipid syndrome.
Where it's running
-
Hospital Universitario Infanta Leonor
Madrid, Madrid, Spain Recruiting -
Hospital Universitario Infanta Sofía
Madrid, Madrid, Spain Recruiting
Study contacts
- Principal investigator: Anabel Franco-Moreno, MD, PhD — Sociedad Española De Medicina Interna
- Study coordinator: Anabel Franco Moreno, MD, PhD
- Email: afranco278@hotmail.com
- Phone: +34686102661
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Anifrolumab for adults with primary antiphospholipid syndrome
This phase II pilot tests whether weekly subcutaneous anifrolumab is safe and tolerable in adults with primary antiphospholipid syndrome while they continue their standard care.
-
Risk tool for blood-clotting problems in adolescents and women with PCOS
This project will try to build a risk model to spot decreased protein C or S and other clotting abnormalities in females aged 14–45 who have PCOS.
-
Long-term follow-up of adults with antiphospholipid syndrome
This project will test how often blood clots come back and which factors affect recurrence in adults with antiphospholipid syndrome.
-
YTS109 cell therapy for relapsed/refractory autoimmune diseases
This trial will try a single infusion of YTS109 immune cells to see if they are safe and help adults aged 18–65 with relapsed or refractory autoimmune diseases such as lupus, Sjogren’s syndrome, inflammatory myopathy, or ANCA-associated vasculitis.
-
YTS109 cell therapy for relapsed or refractory autoimmune diseases
This trial will try a single infusion of YTS109 cells to see if they are safe and help adults (18–65) with relapsing or refractory autoimmune diseases such as SLE, lupus nephritis, systemic sclerosis, inflammatory myopathy, or ANCA-associated vasculitis.
-
YTS109 cell therapy for relapsed or refractory systemic autoimmune diseases
This trial will try a single infusion of YTS109 cells to see if it's safe and helps adults 18–65 with relapsed or refractory systemic autoimmune diseases such as SLE, systemic sclerosis, inflammatory myopathies, ANCA-associated vasculitis, or antiphospholipid syndrome.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.